The combination of dabrafenib and MEK inhibitor trametinib produced substantial antitumor activity (ORR, 66.7%) with durable responses (median PFS, 10.2 months) in previously treated BRAFV600E-mutant NSCLC patients [5]. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.